Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2026)

Raphael Pharmaceutical has disclosed Research & Development across 7 years of filings, most recently posting $40000.0 for Q2 2026.

• In Q2 2026, Research & Development fell 71.63% year-over-year to $40000.0; the TTM figure through Jun 2026 stood at $554000.0 (up 2.97% YoY), while the FY2025 annual figure was $631000.0, down 18.69% from the prior year.
• Research & Development came in at $40000.0 for Q2 2026 at Raphael Pharmaceutical, down from $141000.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $676000.0 in Q4 2022 to a low of -$348000.0 in Q4 2023.
• Average Research & Development over 5 years is $193142.9, with a median of $151500.0 recorded in 2024.
• Year-over-year, Research & Development slumped 151.48% in 2023 and soared 487.5% in 2025.
• Over 5 years, Research & Development stood at $676000.0 in 2022, then tumbled by 151.48% to -$348000.0 in 2023, then soared by 160.63% to $211000.0 in 2024, then slumped by 33.18% to $141000.0 in 2025, then tumbled by 71.63% to $40000.0 in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $40000.0 in Q2 2026, $141000.0 in Q2 2025, and $211000.0 in Q4 2024.